1	Determinants of primaquine and carboxyprimaquine exposures in children and adults with
2	Plasmodium vivax malaria
3	Running title: Primaquine exposures in vivax malaria
4	
5	Cindy S Chu ^{1,2} , James A Watson ^{2,3,*} , Aung Pyae Phyo ¹ , Htun Htun Win ¹ , Widi Yotyingaphiram ¹ , Suradet
6	Thinraow ¹ , Nay Lin Soe ¹ , Aye Aye Aung ¹ , Pornpimon Wilaisrisak ¹ , Kanokpich Puaprasert ⁴ , Mallika Imwong ⁴ ,
7	Warunee Hanpithakpong ³ , Daniel Blessborn ^{2,3} , Joel Tarning ^{2,3} , Stéphane Proux ¹ , Clare Ling ^{1,2} , François H
8	Nosten ^{1,2} , Nicholas J White ^{2,3}
9	
10	¹ Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical
11	Medicine, Mahidol University, Mae Sot, Thailand
12	² Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
13	Oxford, Oxford, UK
14	³ Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,
15	Bangkok, Thailand
16	⁴ Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol
17	University, Bangkok, Thailand.
18	
19	
20	Keywords: Plasmodium vivax, primaquine, pharmacokinetics, relapse, chloroquine,
21	dihydroartemisinin-piperaquine
22	
23	*Corresponding author: james@tropmedres.ac

24 Abstract

25 Background

26 Primaquine is the only widely available drug for radical cure of *Plasmodium vivax* malaria. There

- is uncertainty whether the pharmacokinetic properties of primaquine are altered significantly in
- 28 childhood or not.
- 29 Methods

30 Glucose-6-phosphate dehydrogenase normal patients with uncomplicated *P. vivax* malaria were

31 randomized to receive either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine

32 (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine; given either as 0.5 mg

33 base/kg/day for 14 days or 1 mg/kg/day for 7 days. Pre-dose day 7 venous plasma

34 concentrations of chloroquine, desethylchloroquine, piperaquine, primaquine and

35 carboxyprimaquine were measured. Methemoglobin levels were measured either daily or on

days 1, 3, 6 and 13, and additionally on day 10 in the primaquine 14-day groups.

37 Results

38 Day 7 primaguine and carboxyprimaguine concentrations were available for 641 patients. After

adjustment for the primaquine mg/kg daily dose, day of sampling, partner drug, and fever

40 clearance, there was a significant non-linear relationship between age and trough primaquine

41 and carboxyprimaquine concentrations, and day methemoglobin levels. Compared to adults 30

42 years of age, children 5 years of age had trough primaquine concentrations 0.53 (95% CI: 0.39-

43 0.73) fold lower, trough carboxyprimaquine concentrations 0.45 (95% CI: 0.35- 0.55) fold lower,

44 and day 7 methemoglobin levels 0.87 (95% CI: 0.58-1.27) fold lower. Increasing concentrations

45 of piperaquine and chloroquine and poor metabolizer *CYP 2D6* alleles were associated with

- 46 higher day 7 primaquine and carboxyprimaquine concentrations. Higher blood methemoglobin
- 47 concentrations were associated with a lower risk of recurrence.
- 48 Conclusion
- 49 Young children have lower primaquine and carboxyprimaquine exposures, and lower levels of
- 50 methemoglobinemia, than adults. Young children may need higher weight adjusted primaquine
- 51 doses than adults.

52 Introduction

53 Primaguine is used for radical cure of *Plasmodium vivax* and *Plasmodium ovale* malaria, for antimalarial chemoprophylaxis and as a single dose gametocytocide in *Plasmodium falciparum* 54 malaria (1). Although the slowly eliminated 8-aminoquinoline tafenoquine has been registered 55 56 in a few countries for radical cure or chemoprophylaxis in adults, and pamaguine and guinocide 57 were once used, primaguine is by far the most widely deployed drug in this class. It is generally agreed that the dosing of antimalarial chemotherapy should be designed to provide equivalent 58 59 exposures to the active antimalarial across the age range (1). There is uncertainty whether or not children have lower exposures to primaguine and its bioactive metabolites than adults for the 60 same weight adjusted doses, and thus whether they should receive higher doses than currently 61 recommended (2–5). Primaguine is combined with either an artemisinin combination treatment 62 (ACT) or chloroquine to prevent relapse of vivax or ovale malaria (radical cure) (1). Primaguine is 63 64 a pro-drug requiring metabolism to bioactive metabolites mainly via the liver cytochrome P450 isoenzyme CYP 2D6 (6). The prevalence of intermediate and non-functioning CYP 2D6 alleles is 65 over 50% in some populations, particularly in Asians (7–9). Decreased CYP 2D6 function, resulting 66 from intermediate or poor metabolizer genotypes, potentially lowers radical cure efficacy (10, 67 11). 68

Chloroquine has been the first-line treatment for the blood stages of *P. vivax* malaria for over 70 years (1). High grade resistance in *P. vivax* remains confined to Oceania and Indonesia (12) but, in the last decade, low grade chloroquine resistance, manifest by earlier appearance of relapses, has been reported increasingly in other locations. Piperaquine (a slowly eliminated bisquinoline), combined with dihydroartemisinin, is a well-tolerated and highly efficacious ACT which provides

an excellent alternative blood stage treatment for *P. vivax* malaria (13). An open label two-way randomized controlled trial, conducted on the Thailand-Myanmar border, showed previously that a 7-day high dose primaquine regimen (1 mg/kg/day), combined either with chloroquine or dihydroartemisinin-piperaquine, was non-inferior to the standard 14-day (0.5 mg/kg/day) regimen (14). This large study allowed investigation of the pharmacokinetic properties of primaquine in adults and children, characterization of the determinants of drug exposures, and correlation with therapeutic outcomes.

81 Methods

82 Clinical trial

This study was conducted by the Shoklo Malaria Research Unit (SMRU), which is located on the 83 northwest Thailand-Myanmar border. Full details of the study have been reported previously 84 (14). In brief, patients who presented to an outpatient clinic with microscopy confirmed 85 uncomplicated *P. vivax* mono-infections were enrolled if they were \geq 6 months old, and if they 86 87 were glucose-6-phosphate dehydrogenase (G6PD) normal by the fluorescent spot test. Patients were excluded if they were pregnant or breastfeeding an infant ≤ 6 months, had a hematocrit 88 \leq 25%, or had received a blood transfusion within 3 months. Written informed consent was 89 90 obtained from patients or from parents or carers of children below 18 years old.

91 Patients were randomized 1:1:1:1 to each of the following groups:

Chloroquine (10 mg base/kg on the first two days of treatment, then 5 mg base/kg on day
 3; Remedica, Ltd., Cyprus) and primaquine (1 mg base/kg/day for 7 days; Government
 Pharmaceutical Organization, Thailand)

95 2. Chloroquine as above and primaquine (0.5 mg base/kg/day for 14 days)

- 96 3. Dihydroartemisinin-piperaquine (dihydroartemisinin 7 mg/kg and piperaquine 55 mg/kg
 97 for 3 days; Guilin Pharmaceutical company, China) and primaquine (1 mg base/kg/day for
 98 7 days)
- 99 4. Dihydroartemisinin-piperaquine as above plus primaquine (0.5 mg base/kg/day for 14
 100 days)

101 Food and drink were given before drug administration. Primaguine was usually started on the 102 same day as the schizonticide (i.e. the first day of treatment) but in a subset of patients it was 103 started on the third day of treatment. Patients were assessed daily while on treatment. Methemoglobin was measured either daily or on days 1, 3, 6 and 13, and additionally on day 10 104 in the primaguine 14-day groups, using a transcutaneous pulse oximeter (Masimo Radical-7®). 105 106 One recruitment clinic did not have access to a transcutaneous oximeter, so 80 study patients 107 did not have methemoglobin measurements. All drug doses were supervised. A venous blood sample for antimalarial drug levels was taken before drug administration on day 108

109 6 (i.e. the 7th day of treatment) +/- 2 days, and plasma was separated and stored at -70°C. Patients 110 were followed at weeks 2 and 4, and then every 4 weeks until 52 weeks. If there was a *P. vivax* 111 recurrence then a venous plasma blood sample for drug levels was taken again. Standard high 112 dose primaquine (0.5 mg base/kg/day for 14 days) and chloroquine were given for the treatment 113 of recurrences. Follow-up was re-started as if newly recruited, and day 6 sampling for drug levels 114 was collected again. The total study duration was 52 weeks from enrolment.

115 Drug measurements

Chloroquine/desethylchloroquine, piperaquine, and primaquine/carboxyprimaquine plasma 116 concentrations were measured using three validated liquid chromatography (LC) – tandem mass 117 118 spectrometry (MS/MS) methods (15–17). The lower limits of quantification (LLOQ) were set to 1.4, 1.5, 1.14 and 4.88 ng/mL for chloroquine/desethylchloroquine, piperaguine, primaguine and 119 carboxyprimaguine, respectively. All three quantification methods were validated according to 120 regulatory standards and three levels of quality control samples were analyzed in triplicate within 121 each batch of clinical samples. Total imprecision (i.e. relative standard deviation) for all quality 122 control samples was below 10% during drug quantification. 123

124 CYP 2D6 genotyping

We carried out a nested case-control genotyping study to assess the effect of CYP 2D6 125 polymorphisms on recurrent vivax malaria. Cases were all patients with a recorded recurrent 126 127 episode of vivax malaria during follow-up and controls were patients without observed recurrences matched by age and sex (in total n=158 patients). The CYP 2D6 gene 128 129 duplications/multiplications and gene deletions were determined by extra-long range polymerase chain reaction (XL-PCR) using a previously published protocol (18). The functional 130 131 CYP 2D6 and nonfunctional CYP2D8 and CYP2D7 genes were then differentiated by intron 2 sequencing (INT2). The variants *1, *2, *4, *5, *10, *39, and *36 were identified with rapid 132 identification of four polymorphic loci by allele-specific oligonucleotide probes using real-time 133 SNPs genotyping. From the CYP 2D6 genotyping result the CYP 2D6 "activity score" was obtained 134 as described previously (15, 19–21). 135

136 Ethics approval

137 This study was approved by both the Mahidol University Faculty of Tropical Medicine Ethics

138 Committee (MUTM 2011-043, TMEC 11-008) and the Oxford Tropical Research Ethics

139 Committee (OXTREC 17-11) and was registered at ClinicalTrials.gov (NCT01640574).

140 Statistical analysis

All drug concentration data were analyzed on the log base 10 scale. Three main generalized 141 142 additive linear regression models were fitted to the log₁₀ primaquine day 7 concentrations; the log_{10} carboxyprimaguine concentrations; and the log_{10} carboxyprimaguine to primaguine ratios. 143 We used the following predictors age (years), mg/kg daily dose of primaguine (the administered 144 mg/kg dose not the target dose), study arm (DHA-piperaquine versus chloroquine), fever 145 clearance time (days), the number of days since start of primaguine dosing (6 versus 4), and the 146 time since the previous primaquine dose (in hours). We excluded drug measurements taken 147 148 outside of a 18-30 hour window after the previous dose (only trough levels approximately one 149 day after dosing), except for those for which the previous dose was given less than 30 minutes before the drug measurement. More than 90% of samples were taken in this window 150 (Supplementary Figure 1). A smooth spline term with 3 degrees of freedom was used to estimate 151 non-linear effects of age. Individual random intercept terms were specified to account for 152 153 multiple day 7 measurements in the same patient. To assess any residual effect of CYP 2D6 diplotypes, we fitted linear regression models to the model residual concentrations with the CYP 154 2D6 activity score as a linear predictor. To estimate the effect of the partner drug concentrations 155 (not available for every day 7 measurement), we fitted separate generalized additive regression 156 157 models to the primaquine and carboxyprimaquine \log_{10} concentrations with either the \log_{10}

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21259877; this version posted July 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

chloroquine+desethychloroquine (assuming equal antimalarial activities of parent drug and metabolite and designated as 'chloroquine' in the remainder of the paper) concentration or the log₁₀ piperaquine concentration as additional predictors.

We fitted a generalized additive regression model to the day 7 blood methemoglobin 161 162 concentrations (expressed as a percentage of the hemoglobin concentration) with age, mg/kg daily dose of primaguine, study arm (DHA-piperaguine versus chloroguine), fever clearance time 163 (days), and days since start of primaquine dosing as predictors. A spline term with 3 degrees of 164 165 freedom was fit to age. Secondary models included the CYP 2D6 activity score (available only for the subset of patients in the nested case control investigation) as an additional covariate, both 166 on the linear scale and as a binary covariate (≤ 0.5 versus >0.5). The activity score has an arbitrary 167 168 scale so it is unclear how best to encode it in regression models (i.e. an activity score of 2 versus 1 is not the same as 1 versus 0). 169

We fitted Cox proportional hazard models to the time to first recurrence (right censored event for patients who did not have a recurrence during follow-up), with continuous predictors: age, partner schizonticidal drug (chloroquine versus piperaquine), and either the log₁₀ primaquine or the log₁₀ carboxyprimaquine day 7 concentration (they are highly co-linear so we fitted two separate models). Additional models included the day 7 methemoglobin levels as an additional predictor (measured in all sites except the one where a transcutaneous pulse oximeter was not available).

The generalized additive models were fitted in R version 4.0.2 using the package *mgcv* version
1.8. The Cox proportional hazard model used the *survival* package version 3.2. Code in the form

of an RMarkdown script along with all analyzed data are available on an accompanying github
 repository for full reproducibility (https://github.com/jwatowatson/Primaguine day7).

181 Results

182 Between February 2012 and July 2014, 680 patients with uncomplicated acute P. vivax malaria were enrolled. In total 641 patients had at least one day 7 plasma primaguine and 183 184 carboxyprimaguine concentration measured, either during the enrollment episode or during a recurrent P. vivax episode (there were a total of 720 episodes with day 7 concentrations including 185 186 patients with multiple episodes). For 692 of these day 7 concentrations, the corresponding 187 plasma chloroquine or piperaquine concentration was also available (measured from the same blood sample). We excluded 41 drug measurements considered not to be trough levels (see 188 Methods) resulting in a total of 679 day 7 measurements included in the analysis. 189

In total, 71 of the patients with measured primaquine and carboxyprimaquine concentrations were 6 to \leq 10 years of age (median weight 20kg, range 13-30kg), and 34 were \leq 5 years of age (median weight 14kg, range 8-20kg) (Table 1). Three patients were less than 3 years old, and the youngest was 1 year 6 months old. Fever and parasite clearance times were similar across all age groups. The proportion of patients with microscopy detected gametocytemia was higher in the older age groups >10 years.

196 Effect of age

After adjustment for the daily mg/kg primaquine dose, the number of days of dosing, the fever clearance times, and the partner drug (piperaquine versus chloroquine), there was a significant non-linear association between age and day 7 primaquine trough concentration (p<10⁻¹⁶ for the

smooth spline term fit to age) and day 7 carboxyprimaquine trough concentration ($p < 10^{-16}$ for the smooth spline term fit to age) (Figure 1). For both primaquine and carboxyprimaquine, increasing age correlated with higher trough levels. The strongest effect was seen for the carboxyprimaquine trough levels. Thus the ratio of carboxyprimaquine to primaquine was also associated with age, with an approximate doubling when comparing patients aged ≤ 5 years versus patients 30 years or older (Figure 1).

206 Effect of partner drug

Our previously reported healthy volunteer studies showed that co-administration of piperaquine 207 208 and chloroquine both increased exposures to primaquine and carboxyprimaquine (15, 16). In this 209 study of patients with vivax malaria, a ten-fold increase in the chloroquine day 7 concentration 210 was associated with a 2.5 fold increase in day 7 primaguine concentrations (95% CI: 1.9 to 3.1; 211 p=0.0003), and a 2.0 fold increase in day 7 carboxyprimaguine concentrations (95% CI: 1.7 to 2.4; 212 p=0.0002). A ten-fold increase in the piperaguine day 7 concentrations was associated with a 2.5 fold increase in primaguine concentrations (95% CI: 1.9 to 3.2; p=0.0005), and a 2.5 fold increase 213 in carboxyprimaguine concentrations on day 7 (95% CI: 2.1 to 3.0; $p=10^{-7}$). Scatterplots showing 214 215 the univariate relationships between the partner drug concentrations and primaguine/carboxyprimaguine concentrations are shown in Supplementary Figure 2. Treatment 216 217 with chloroquine or piperaquine had no statistically significant effect on the 218 carboxyprimaguine/primaguine ratios.

219 Effect of CYP 2D6 genotypes

CYP 2D6 genotypes were determined in 154 patients. The estimated CYP 2D6 allele frequencies 220 in this population were as follows: 25% for *1; 23% for *2; 2% for *4; 10% for *5; 38% for *10; 221 222 0.5% for *39; and 1% for *36. Alleles *4, *5, and *36 are considered null-metabolizer alleles (enzyme activity score of 0); *10 is a poor metabolizer allele (activity score of 0.25); and *1 and 223 *39 are normal metabolizer alleles (activity score of 1). In total, there were 3 patients with an 224 activity score of 0 (non-metabolizers) and 36 patients with activity scores of either 0.25 or 0.5 225 (poor metabolizers). For primaguine day 7 plasma concentrations, model residuals (defined as 226 the observed concentration minus the predicted concentration, both on the log scale, where the 227 model is based on age, mg/kg dose, fever clearance, time since last dose, number of days of 228 dosing, and partner drug), were correlated significantly with the genotype-defined CYP 2D6 229 enzyme activity scores (Figure 2; ρ = -0.2, p=0.004). Patients with low CYP 2D6 activity scores had, 230 on average, higher observed concentrations of primaguine than predicted (i.e. positive 231 residuals), whereas patients with normal activity scores had lower concentrations than expected 232 233 (i.e. negative residuals). For plasma carboxyprimaguine concentrations, a trend in the same 234 direction was observed, but the correlation was substantially smaller, and it was not significant (p=0.1). 235

236 Methemoglobinemia and hemolysis

Primaquine causes predictable methemoglobinemia. As reported previously methemoglobin
concentrations rose over the first week of primaquine treatment, and then plateaued in the 14day primaquine groups. The day 7 values were usually the peak recorded values
(Supplementary Figure 3). Methemoglobin (expressed as a percentage of the hemoglobin

241	concentration) was lower in children than in young adults ($p < 10^{-16}$ for a spline term fit to age in
242	a generalized additive regression model, Figure 3A), and was lower in patients with loss of
243	function CYP 2D6 polymorphisms (Figure 2C; absolute decrease of 1.2 percentage points in the
244	mean day 7 methemoglobin level in patients with an activity score \leq 0.5 compared to patients
245	with an activity score > 0.5; 95% CI: 0.1-2.3%, <i>p</i> =0.04). Day 7 methemoglobin levels were
246	associated with both primaquine and carboxyprimaquine day 7 plasma concentrations. A ten-
247	fold increase in primaquine day 7 concentrations was associated with an absolute increase of
248	0.7 percentage points in day 7 methemoglobin levels (95% CI: 0.14-1.23), and a ten-fold
249	increase in carboxyprimaquine concentrations was associated with an absolute increase of 1.1
250	percentage points in day 7 methemoglobin levels (95% CI: 0.5 – 2.0). Four patients stopped
251	taking primaquine because of elevated methemoglobin levels and associated symptoms. Two of
252	these patients stopped on day 5 and, as the day 6 primaquine dose was not administered, they
253	had low day 7 primaquine and carboxyprimaquine levels. One of these patients had a recorded
254	methemoglobin level of 20.9% on day 6 followed by 18.1% on day 7. The other three patients
255	had peri-oral cyanosis (blue lips). Their peak recorded methemoglobin levels were between 10
256	and 12%.
257	There was no relationship between age and hemolysis defined as the percentage drop in

here was no relationship between age and hemolysis defined as the percentage drop in
 hematocrit between baseline and day 7 (Figure 3B).

259 Primaquine exposure and *P. vivax* recurrence

We did an exploratory analysis of the relationship between primaquine exposures and times to the first *P. vivax* recurrence. A total of 564 patients had recorded day 7 drug levels and methemoglobin levels, and 70 had at least one recurrence during follow-up. After adjusting for

age and partner drug, day 7 concentrations of primaquine and carboxyprimaquine were not
associated with the risk of recurrence, but a 1% absolute increase in day 7 methemoglobin was
associated with a hazard ratio for recurrence of 0.9 (95% CI: 0.85-0.99, p=0.02). Two of the
three patients with a *CYP 2D6* activity score of 0 had a *P. vivax* recurrence, and one of them had
2 recurrences (the interval between recurrences was >65 days). Studies are ongoing to
characterize the relationship between *CYP 2D6* genotypes and risk of *P. vivax* relapse in this
population.

270 Discussion

271 Radical cure of *P. vivax* malaria is necessary to prevent relapses. Relapses of vivax malaria are a major cause of morbidity and developmental delay in children living in endemic areas, so 272 273 optimization of primaquine dosing is critical in this age group. The higher *P. vivax* relapse rates in 274 children compared with adults living in endemic areas observed in some studies (22) are attributed usually to lower levels of immunity, but lower drug exposures could also be a 275 276 contributory factor. For many antimalarial drugs, exposures in children are lower than in adults and an increase in the weight adjusted dosing is needed (1). The limited pharmacokinetic 277 278 evidence to date for primaguine does not provide a clear picture, with a study from Papua New 279 Guinea suggesting little difference between adults and older children (2), whereas a study of single dose primaguine (used as a P. falciparum gametocytocide) in Tanzania (3) and a study of 280 281 primaguine for *P. vivax* radical cure in Brazil (4) both suggesting that younger children had lower 282 exposures. The relationship between plasma primaquine concentrations and antimalarial effect is complex. Primaguine is metabolized rapidly (elimination half-life ~5 hours) via monoamine 283 284 oxidase to a biologically inert metabolite carboxyprimaguine and, through a separate pathway,

285 mainly via CYP 2D6, to several active hydroxylated metabolites (6, 23). The exact mechanism of 286 antimalarial action remains uncertain. Recent laboratory studies suggest that these unstable hydroxylated metabolites are oxidized to guinoneimines generating local hydrogen peroxide -287 which is parasiticidal. The quinoneimines in turn are substrates for cytochrome P450 288 NADPH:oxidoreductase (POR or CPR) resulting in hydrogen peroxide accumulation and 289 augmenting the parasiticidal effect (24). These reactions may mediate both the antimalarial 290 291 therapeutic effects, and also the oxidant hemolytic adverse effects. Alternatively the 292 quinoneimine itself may cause the hemolytic and possibly parasiticidal effects by forming 293 irreversible ligands with heme. There is also evidence for synergy between the 8-aminoquinolines 294 and other quinoline antimalarials in liver stage and blood stage activities (25, 26). The 8aminoquinolines have innate schizonticidal activity as well as radical curative activity and 4-295 296 aminoquinoline antimalarials increase primaguine concentrations (15, 16, 26). Unfortunately, 297 although the metabolic pathway to the production of the active primaguine metabolites has been characterized ex-vivo, no validated measure of their concentrations, or of their more stable 298 299 metabolites, in whole blood, plasma, or urine has yet been correlated with antimalarial therapeutic responses in-vivo. Thus, measurement of primaguine and carboxyprimaguine 300 concentrations does not provide a direct correlate of antimalarial activity. Furthermore, because 301 302 the apparent volume of distribution of carboxyprimaguine is not known, the proportion of parent 303 drug that passes through this inactive metabolic pathway cannot be estimated.

304

305 This large study of day 7 "trough" primaquine and carboxyprimaquine plasma concentrations 306 shows clearly that exposures to both parent compound and inactive metabolite are lower in

307 children than in adults. This is unlikely to be explained by lower oral bioavailability as primaguine 308 is generally well absorbed, the children in the study were clinically well by seven days after starting treatment (14), all doses were observed, and only 7 children ≤ 10 years old (≤ 27 kg) 309 vomited. It presumably reflects either larger primaguine (and carboxyprimaguine) distribution 310 311 volumes, or increased clearance, or both. The lower ratio of carboxyprimaguine to primaguine in children may also be explained by these age-related pharmacokinetic changes. Although 312 313 greater diversion down the bioactivating CYP pathway cannot be excluded as an explanation for 314 these findings- there is no convincing evidence for augmented drug efficacy (e.g. no relationship with fever or parasite clearance times) or increased hemolytic toxicity in children to support this. 315 Furthermore, in this study, methemoglobinemia was lower in children than in young adults, 316 indicating that formation of oxidant metabolites was reduced (27). Lower methemoglobin 317 318 concentrations were associated with an increased risk of *P. vivax* recurrence. The importance of 319 CYP 2D6 primaguine bioactivation in the generation of oxidant metabolites was evidenced by the lower levels of methemoglobinemia in patients with loss of function CYP 2D6 polymorphisms 320 321 (Figure 2C). Taken together this evidence strongly suggests that children have lower exposures to the biologically active metabolites of primaguine than do adults receiving the same weight 322 adjusted doses. 323

324

This study was sufficiently large that the influence of other covariates affecting primaquine exposures could be examined. We have reported previously that co-administration of quinoline or structurally related antimalarials increases primaquine and carboxyprimaquine concentrations (15, 16). This was confirmed in this study. The effects on the parent compound of chloroquine

and piperaquine were similar whereas piperaquine had a larger effect on carboxyprimaquine. In
Asia loss of function *CYP 2D6* genetic polymorphisms (mainly the *10 allele) are common. In this
study low *CYP 2D6* activity scores (derived from the genotype) were associated with higher
primaquine levels and lower levels of methemoglobinemia as would be expected from reduced
metabolic conversion through this bioactivation pathway.
There are several limitations to this study. This analysis is limited to drug concentrations at one

time point during radical cure treatment providing a limited description of drug exposures. Very

336 young children are under-represented, and the analysis does not include any infants < 1 year old.

337 In addition, *CYP 2D6* genotyping was not performed in all patients.

338 There is no evidence that the adverse effects of primaquine are significantly worse in children

than adults. The main therapeutic implication of this large pharmacometric evaluation is that

340 children may require larger weight adjusted doses of primaquine than adults.

341 Funding

This work was supported by the Wellcome Trust [grant number 089179/Z/09/Z] to NJW. CSC, JW,

343 APP, JT, CL, FHN and NJW are supported by the Wellcome Trust [Programme grant number

089179]. CSC, JW, APP, JT, CL, FHN, and NJW are part of the Wellcome Trust Mahidol University

345 Oxford Tropical Medicine Research Programme funded by the Wellcome Trust.

346

347 Acknowledgements

348 This research was funded by The Wellcome Trust. A CC BY or equivalent license is applied to the 349 author accepted manuscript arising from this submission, in accordance with the grant's open

350 access conditions. The authors would like to thank the SMRU staff for their hard wo	ork in
---	--------

- running this study and the MORU Clinical Pharmacology Laboratory in Bangkok for their diligent
- 352 work in sample processing and drug measurements. Special appreciation goes to the
- 353 contributions of Htet Htet Chaw, Nwe Wah Lin, Thida Zin, Say Paw, Naw Eh Shee, Thu Lay Paw,
- 354 Rattanporn Raksapraidee, Moo Koo Paw, the data entry team headed by Jacher
- 355 Wiladphaingern, the logistics team, and the laboratory teams headed by Kanlaya Sriprawat and
- 356 Germana Bancone.
- 357 We would also like to thank the Data Safety and Monitoring Board: Bob Taylor, Charles Woodrow,
- and Professor Nicholas Day for their time and commitment.

359 References

- World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd Edition. World
 Health Organization, Geneva.
- 362 2. Moore BR, Salman S, Benjamin J, Page-Sharp M, Robinson LJ, Waita E, Batty KT, Siba P, Mueller I,
- 363 Davis TME, Betuela I. 2014. Pharmacokinetic properties of single-Dose primaquine in papua new
- 364 guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.
- 365 Antimicrob Agents Chemother 58:432–439.
- 366 3. Gonçalves BP, Pett H, Tiono AB, Murry D. 2017. Age, weight, and CYP2D6 genotype are major
- 367 determinants of primaquine pharmacokinetics in African children. Antimicrob Agents Chemother
 368 Agents Chemother 61:e02590-16.
- 369 4. Vieira MVDF, Matos Lopes TR, Mello AGNC, de Sena LWP, Commons RJ, Vieira JLF. 2020. Doses of
- 370 primaquine administered to children with Plasmodium vivax according to an age-based dose

371 regimen. Pathog Glob Health 114:388–392.

372 5. Gogtay N, Karande S, Kadam P, Momin S, Thatte U. 2021. Evaluation of pharmacokinetics of

- 373 single-dose primaguine in undernourished versus normally nourished children diagnosed with
- 374 Plasmodium vivax malaria in Mumbai. J Postgrad Med 67:75–79.
- 375 6. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard G a,
- 376 Ockenhouse C, Bennett J, Walker L a, Ohrt C, Melendez V. 2013. The metabolism of primaquine
- to its active metabolite is dependent on CYP 2D6. Malar J 12:e212.
- 378 7. Neafsey P, Ginsberg G, Hattis D, Sonawane B. 2009. Genetic polymorphism in cytochrome P450
- 379 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev
- 380 12:334–361.
- 381 8. McGraw J, Waller D. 2012. Cytochrome P450 variations in different ethnic populations. Expert
- 382 Opin Drug Metab Toxicol 8:371–382.
- 383 9. Puaprasert K, Chu C, Saralamba N, Day NPJ, Nosten F, White NJ, Dondorp AM, Imwong M. 2018.
- Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen
 population study. Malar J 17:427.
- 10. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC. 2013. Primaquine failure and cytochrome P-

387 450 2D6 in Plasmodium vivax malaria. N Engl J Med 369:1380–1381.

- 388 11. Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, Chand K, Gayatri A, Instiaty,
- 389 Soebianto S, Crenna-Darusallam C, Djoko D, Hasto BD, Meriyenes D, Wesche D, Nelwan EJ,
- 390 Sutanto I, Sudoyo H, Setiabudy R. 2018. Association of Impaired Cytochrome P450 2D6 Activity
- 391 Genotype and Phenotype with Therapeutic Efficacy of Primaguine Treatment for Latent
- 392 Plasmodium vivax Malaria. JAMA Netw Open 1:e181449.
- 393 12. Price RN, von Seidlein L, Valecha N, Nosten FH, Baird JK, White NJ. 2014. Global extent of
- 394 chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis
 395 14:982–91.
- 13. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, Auburn S,

397	Chand K, Chau NH	, Cheah PY, Dong LT, Dhorda N	<i>I</i> , Degaga TS, Devine A, Ekawati LL, Fahmi F,
-----	------------------	-------------------------------	--

- 398 Hailu A, Hasanzai MA, Hien TT, Khu H, Ley B, Lubell Y, Marfurt J, Mohammad H, Moore KA,
- 399 Naddim MN, Pasaribu AP, Pasaribu S, Promnarate C, Rahim AG, Sirithiranont P, Solomon H,
- 400 Sudoyo H, Sutanto I, Thanh NV, Tuyet-Trinh NT, Waithira N, Woyessa A, Yamin FY, Dondorp A,
- 401 Simpson JA, Baird JK, White NJ, Day NP, Price RN. 2019. Short-course primaquine for the radical
- 402 cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority
- 403 trial. Lancet 394:929–938.
- 404 14. Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, Thinraow S, Wilairisak P,
- 405 Raksapraidee R, Carrara VI, Paw MK, Wiladphaingern J, Proux S, Bancone G, Sriprawat K, Lee SJ,
- 406 Jeeyapant A, Watson JA, Tarning J, Imwong M, Nosten F, White NJ. 2018. Chloroquine versus
- 407 dihydroartemisinin-piperaquine with standard High-dose primaquine given either for 7 days or

408 14 days in Plasmodium vivax malaria. Clin Infect Dis 68:1311–1319.

- 409 15. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W,
- 410 Chotsiri P, Wattanakul T, Panapipat S, Lee SJ, Day NPJ, White NJ. 2014. Open-Label Crossover
- 411 Study of Primaguine and Dihydroartemisinin-Piperaguine Pharmacokinetics in Healthy Adult Thai
- 412 Subjects. Antimicrob Agents Chemother 58:7340–7346.
- 413 16. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ,
- 414 Hanpithakpong W, Hanboonkunupakarn B, Day NPJ, Ashley E a, White NJ. 2014. Pharmacokinetic
- 415 interactions between primaquine and chloroquine. Antimicrob Agents Chemother 58:3354–3359.
- 416 17. Kaewkhao K, Chotivanich K, Winterberg M, Day NP, Tarning J, Blessborn D. 2019. High sensitivity
- 417 methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS.
- 418 Bioanalysis 11:333–347.
- 419 18. Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, LLerena A. 2005. Development of a
 420 PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential

421 use. Biotechniques 39:571–574.

- 422 19. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2008. The CYP2D6 activity
 423 score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol
- 424 Ther 83:234–242.
- 425 20. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling M V.,
- 426 Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A. 2020. Standardizing CYP2D6 Genotype to Phenotype
- 427 Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation
- 428 Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci 13:116–124.
- 429 21. Spring MD, Lon C, Sok S, Sea D, Wojnarski M, Chann S, Kuntawunginn W, Heng TK, Nou S,
- 430 Arsanok M, Sriwichai S, Vanachayangkul P, Lin JT, Manning JE, Jongsakul K, Pichyangkul S,
- 431 Satharath P, Smith PL, Dysoley L, Saunders DL, Waters NC. 2020. Prevalence of CYP2D6
- 432 genotypes and predicted phenotypes in a cohort of cambodians at high risk for infections with
- 433 plasmodium vivax. Am J Trop Med Hyg 103:756–759.
- 434 22. Luxemburger C, van Vugt M, Jonathan S, McGready RM, Looareesuwan S, White NJ, Nosten FH.
- 435 1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg
- 436 93:433–438.
- 437 23. Avula B, Tekwani BL, Chaurasiya ND, Fasinu P, Dhammika Nanayakkara NP, Bhandara Herath
- 438 HMT, Wang Y-H, Bae J-Y, Khan SI, Elsohly MA, McChesney JD, Zimmerman PA, Khan IA, Walker
- 439 LA. 2018. Metabolism of primaquine in normal human volunteers: investigation of phase I and
- 440 phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-
- 441 quadrupole time-of-flight mass spectrometry. Malar J 17:294.
- 442 24. Camarda G, Jirawatcharadech P, Priestley RS, Saif A, March S, Wong MHL, Leung S, Miller AB,
- 443 Baker DA, Alano P, Paine MJI, Bhatia SN, O'Neill PM, Ward SA, Biagini GA. 2019. Antimalarial
- 444 activity of primaquine operates via a two-step biochemical relay. Nat Commun 10:1–9.

- 445 25. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. 1955. Potentiation
- 446 of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med
- 447 46:301–306.
- 448 26. Baird JK. 2019. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev 32:1–68.
- 449 27. Umbreit J. 2007. Methemoglobin--it's not just blue: a concise review. Am J Hematol 82:134–144.

451 Tables and Figures

452 Table 1. Patient characteristics at enrolment by age group

	Age group			
	≤5 years	≤5 years 6-10 years 11-15 years		≥16 years
	n=34	n=71	n=118	n=418
Chloroquine+Primaquine-7	8 (5%)	22 (13%)	29 (18%)	104 (64%)
Chloroquine+Primaquine-14	10 (6%)	18 (11%)	29 (18%)	103 (65%)
DHAP+Primaquine-7	7 (4%)	15 (10%)	37 (24%)	98 (62%)
DHAP+Primaquine-14	9 (6%)	16 (10%)	23 (14%)	113 (70%)
Median age years (IQR, range)	4 (3.2-5, 1.5-5)	8 (6-10, 5.1-10)	13 (12-14, 11- 15)	28 (20-39, 16- 63)
Median weight, kg (IQR, range)	14 (12-16, 8- 20)	20 (16-23, 13- 30)	35 (29-43, 21- 57)	52 (47-56, 31- 88)
Median Body Mass Index, kg/m ² (IQR, range)	15 (14-16, 13- 18)	14 (14-15, 11- 18)	17 (15-18, 12- 23) ¹	20 (19-22, 13- 36)
History of fever, n (%)	34 (100%)	71 (100%)	118 (100%)	411 (98%)
Median temperature >37.5°C, (IQR, range)	37.5 (36.7- 38.2, 36-40)	37.4 (36.8- 38.2, 36-40.1)	37.6 (37-38.5, 36-40.9) ¹	37.3 (36.8- 38.1, 36-40.9)
Fever clearance; days (range)	0 (0-4)	0 (0-3)	1 (0-2)	0 (0-4)
Geometric mean parasitemia, parasites/µL (range)	3096 (16- 40,192)	3633 (16- 221,056)	4886 (16- 75,109)	3804 (16- 816,400)
Parasite clearance, days (range)	2 (1-4)	2 (1-3)	2 (1-4)	2 (1-5)
Gametocytemia, n (%)	23 (68%)	56 (79%)	104 (88%)	352 (84%)
Median chloroquine level ^a , ng/mL (range)	54.3 (6.4-115)	50.1 (27.3-138)	56.1 (27.6-161)	77.9 (26.9-248)
Median piperaquine level ^a , ng/mL (range)	37.5 (15.3-109)	29.4 (10-7- 78.2)	35.3 (7.7-131)	37 (7.3-181)
Median carboxyprimaquine level ^a , ng/mL (range)	261 (29-1410)	406 (9-1590)	563 (40-2740)	793 (59-4710)
Median primaquine level ^a , ng/mL (range)	3.5 (1.1-43.8)	3.8 (0.9-349)	5.2 (0.9-106)	6.9 (1-293)
Median carboxyprimaquine: primaquine ratio ^a , (range)	86 (12-207)	97 (4-256)	98 (23-516)	106 (2-564)

453

454 Primaquine-7: primaquine dosing 1 mg/kg/day for 7 days


- 455 Primaquine-14: primaquine dosing 0.5 mg/kg/day for 14 days
- 456 Numeric superscript denotes the number of missing values
- ^a Only data from the first episode are included

458 Legends to Figures

- 459 Figure 1: The effect of age on primaquine and carboxyprimaquine exposures in patients with acute vivax
- 460 malaria.
- 461 Panel A: age versus mg/kg primaquine daily dose;
- 462 Panel B: age versus the primaquine concentration on day 7;
- 463 Panel C: age versus the carboxyprimaquine concentration on day 7;
- 464 Panel D: age versus the ratio of the day 7 carboxyprimaquine to primaquine concentration.
- 465 The black lines show model fits using a generalized additive model with a smooth spline term for age
- and adjusting for daily mg/kg dose; number of days of primaquine received, time since last dose, partner
- 467 drug and fever clearance time (dashed: mean predicted concentration for 1mg/kg daily; solid: mean
- 468 predicted concentration for 0.5 mg/kg daily).
- 469
- 470 Figure 2: The relationship between *CYP 2D6* genotypes and primaquine and carboxyprimaquine
- 471 exposure, and day 7 methemoglobin levels. In panels A and B, the y-axis shows the model residuals
- 472 (observed minus predicted) for the main model of exposure (adjusting for age, daily mg/kg primaquine
- dose, partner drug, and fever clearance time). In panel C, the y-axis shows the observed day 7
- 474 methemoglobin %. In all three panels the x-axis is the activity score predicted from the CYP 2D6
- 475 diplotype (20). Each box-and-whisker plot shows the median value, the interquartile range and the
- 476 range. The box widths are proportional to the square-roots of the number of observations per activity
- 477 score.

- 479 Figure 3: Age and drug exposure relationships with hemolysis and methemoglobinemia.
- 480 Panel A: Age and day 7 methemoglobin
- 481 Panel B: Age and the day 7 change in hematocrit from baseline.

482	Panel C: Day 7 methemoglobin and pre-dose primaquine concentrations.
483	Panel D: Day 7 methemoglobin and pre-dose carboxyprimaquine concentrations. In panels A&B the
484	black lines show model fits under a generalized additive model with a smooth spline term for age and
485	adjusting for daily mg/kg dose; number of days of primaquine received, the time since last dose, and
486	G6PD deficiency (dashed: mean predicted concentration for 1mg/kg daily; solid: mean predicted
487	concentration for 0.5 mg/kg daily).
488	
489	Supplementary Figure 1: time since previous dose versus the primaquine and carboxyprimaquine blood
490	concentration. The dashed vertical lines show the 5 th and 95 th quantiles of the time since last dose.
491	
492	Supplementary Figure 2: Primaquine and carboxyprimaquine log concentrations versus chloroquine and
493	piperaquine log concentrations measured at the same timepoints. The dashed lines show a univariate
494	linear regression to highlight the trend.
495	
496	Supplementary Figure 3: Methemoglobin as function of the time since starting primaquine (black
497	circles: 0.5 mg/kg target dose for 14 days; red circles: 1 mg/kg target dose for 7 days). We added
498	random jitter to the time in days for visual clarity.
499	
500	Supplementary Table 1: Estimated regression coefficients (standard errors) for the linear terms in the
501	main models. NI: not included. Age is included in these models as a non-linear term and so it is excluded
502	from this table (effects are shown in Figures 1 & 3). For the time to recurrence model, the coefficients
503	and standard errors are given on the linear scale (hazard ratio is given by the exponential of the
504	coefficient).





506 Figure 1






Figure 2











514515 Supplementary Figure 1





517 Supplementary Figure 2



Days since start of primaquine

519 Supplementary Figure 3

Outcome	Regression	Dose	Partner	Days of	Fever	CYP 2D6	G6PD	Methb
variable	type	(mg/kg)	drug	primaquine	clearance	activity	deficiency	(%)
					(days)	score < 1		
PQ (log	linear	1.14	0.014	0.038 (0.047)	-0.017	NI	NI	NI
ng/mL)		(0.06)	(0.03)		(0.021)			
CPQ (log	linear	0.85	-0.020	0.042 (0.032)	-0.027	NI	NI	NI
ng/mL)		(0.040)	(0.021)		(0.014)			
log CPQ/PQ	linear	-0.28	-0.039	-0.0040	-0.0086	NI	NI	NI
		(0.043)	(0.022)	(0.035)	(0.016)			
Methb (%)	linear	3.14	NI	-1.11 (0.77)	NI	-1.21	-0.43 (0.86)	NI
		(0.92)				(0.59)		
Hb	linear	-2.43	-2.90	3.07 (1.13)	-2.10	NI	-12.0 (1.67)	NI
reduction		(1.43)	(0.73)		(0.50)			
(%)								
Time to	Сох	NI	-0.23	NI	NI	NI	NI	-0.09
recurrence	proportional		(0.24)					(0.039)
	hazards							

520

521 Supplementary Table 1